Tumor vaccines in renal cell carcinoma

World Journal of Urology

Volumn 26, Issue 2, 2008, Pages 147-154

  Uemura, Hirotsugu ^a   Velasco, Marco A ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Active specific immunotherapy; Renal cell carcinoma; Tumor vaccine

Indexed keywords

CANCER VACCINE; MTORC1 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ANTAGONISM; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR;

CANCER VACCINES; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; PROTEIN-TYROSINE KINASES; TRANSCRIPTION FACTORS;

EID: 42349100770     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0246-3     Document Type: Article

References (56)

1. Ritchie AWS, deKernion JB (1987) The natural history and clinical features of renal carcinoma. Semin Nephrol 7:131-139
2. Escudier B, Eisen T, Stadler WM, et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
3. Motzer RJ, Huston TE, Tomczak P, et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
4. Tykkä H, Oravisto KJ, Lehtonen T, et al (1978) Active specific immunotherapy of advanced renal-cell carcinoma. Eur Urol 4:250-258
5. Tykkä H (1981) Active specific immunotherapy with supportive measures in the treatment of advanced palliatively nephrectomised renal adenocarcinoma. A controlled clinical study. Scand J Urol Nephrol Suppl 63:1-107
6. Sahasrabudhe DM, deKernion JB, Pontes JE, et al (1986) Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Mod 5:581-594
7. Fowler JE Jr (1986) Failure of immunotherapy for metastatic renal cell carcinoma. J Urol 135:22-25
8. Schärfe T, Müller S, Riedmiller H, et al (1989) Immunotherapy of metastasizing renal cell carcinoma. Results of a multicentered trial. Urol Int 44:1-4
9. Kübler H, Vieweg J (2006) Vaccines in renal cell carcinoma. Semin Oncol 33:614-624
10. Ranieri E, Gigante M, Storkus WJ, et al (2007) Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer. Clin Exp Immunol 147:395-400
11. Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6:404-414
12. Brossart P, Stuhler G, Flad T, et al (1998) Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58:732-736
13. Flad T, Spengler B, Kalbacher H, et al (1998) Direct identification of major histocompatibility complex class I-bound tumor-associated peptides antigens of a renal carcinoma cell line by a novel mass spectrometric method. Cancer Res 58:5803-5811
14. Neumann E, Engelsberg A, Decker J, et al (1998) Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based immunotherapies? Cancer Res 58:4090-4095
15. Vissers JL, De Vries IJ, Schreurs MW, et al (1999) The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen(HLA)-A2. 1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 59:5554-5559
16. Tso CL, Zisman A, Pantuck A, et al (2001) Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/ monocytecolony stimulating factor. Cancer Res 61:7925-7933
17. Uemura H, Fujimoto K, Tanaka M, et al (2006) A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 12:1768-1775
18. Iiyama T, Udaka K, Takeda S, et al (2007) WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51:519-530
19. Oki Y, Younes A (2004) Heat shock protein-based cancer vaccines. Expert Rev Vaccines 3:403-411
20. Guida M, Colucci G. (2007) Immunotherapy for metastatic renal cell carcinoma: Is it a therapeutic option yet? Ann Oncol 18:149-152
21. Kurth KH, Marquet R, Zwartendijk J, Warnaar SO. (1987) Autologous anticancer antigen preparation for specific immunotherapy in advanced renal cell carcinoma. Eur Urol 13:103-109
22. McCune CS, Schapira DV, Henshaw EC (1981) Specific immunotherapy of advanced renal carcinoma: Evidence for the polyclonality of metastases. Cancer 47:1984-1987
23. Schärfe T, Müller S, Riedmiller H, Jacobi GH, et al (1989) Immunotherapy of metastasizing renal cell carcinoma. Results of a multicentered trial. Urol Int 44:1-4
24. Galligioni E, Quaia M, Merlo A, et al (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: Five-year results of a prospective randomized study. Cancer 77:2560-2566
25. Schwaab T, Heaney JA, Schned AR, et al (2000) A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: Clinical outcome and analysis of immunological parameters. J Urol 163:1322-1327
26. Jocham D, Richter A, Hoffmann L, et al (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363:594-599
27. Kommu S. (2004) Renal-cell carcinoma: Vaccination and risk of tumour progression. Lancet 363:1557
28. Frankenberger B, Regn S, Geiger C, et al (2005) Cell-based vaccines for renal cell carcinoma: Genetically-engineered tumor cells and monocyte-derived dendritic cells. World J Urol 23:166-174
29. Simons JW, Jaffee EM, Weber CE, et al (1997) Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57:1537-1546
30. Antonia SJ, Seigne J, Diaz J, et al (2002) Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 167:1995-2000
31. Pizza G, De Vinci C, Lo Conte G, et al (2004) Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. Folia Biol (Praha) 50:175-183
32. Amato RJ. (2003) Vaccine therapy for renal cell carcinoma. Rev Urol 5:65-71
33. Avigan D. (2004) Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin Cancer Res 10:6347S-6352S
34. Su Z, Dannull J, Heiser A, et al (2003) Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63:2127-2133
35. Wierecky J, Müller MR, Wirths S, et al (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66:5910-5918
36. Kim JH, Lee Y, Bae YS, et al (2007) Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol. doi: 10.1016/ j.clim.2007.07.014
37. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, et al (2007) Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 30:116-122
38. Matsumoto A, Haraguchi K, Takahashi T, et al (2007) Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. Int J Urol 14:277-283
39. Avigan DE, Vasir B, George DJ, et al (2007) Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 30:749-761
40. Date Y, Kimura A, Kato H, et al (1996) DNA typing of the HLA gene population study and identification of four new alleles in Japanese. Tissue Antigens 47:93-101
41. Wood CG, Escudier B, Gorelov S, et al (2004) A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC). A preliminary report. J Clin Oncol 22: 1925
42. Brossart P, Heinrich KS, Stuhler G, et al (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309-4317
43. Achtar MS, Ibrahim RA, Herrin VE, et al (2004) Vaccine therapy with tumor specific mutated VHL peptides in adult cancer patients with renal cell carcinoma. J Clin Oncol 22:185S
44. Liao SY, Brewer C, Zavada J, et al (1994) Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 145:598-609
45. Saarnio J, Parkkila S, Parkkila AK, et al (1997) Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153:279-285
46. Tuner JR, Odze RD, Crum FCP, et al (1997) MN antigen expression in normal, preneoplastic, and neoplastic esophagus: A clinicopathological study of a new cancer-associated biomarker. Human Pathol 28:740-744
47. Swinson DE, Jones JL, Richardson D, et al (2003) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. Clin Oncol 21:473-482
48. Shimizu K, Uemura H, Yoshikawa M, et al (2003) Induction of antigen specific cellular immunity by vaccination with peptides from MN/CA IX in renal cell carcinoma. Oncol Rep 10:1307-1311
49. Dunn GP, Bruce AT, Ikeda H, et al (2002) Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 3:991-998
50. Rescigno M, Avogadri F, Curigliano G. (2007) Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta 1776:108-123
51. Parmiani G, Castelli C, Dalerba P, et al (2002) Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?. J Natl Cancer Inst 94:805-818
52. Dillman R, Barth N, Vandermolen L, et al (2004) Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm 19:570-580
53. Tani K, Azuma M, Nakazaki Y, et al (2004) Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: Clinical and immunological findings. Mol Ther 10:799-816
54. Moiseyenko VM, Danilov AO, Baldueva IA, et al (2005) Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: Miscellaneous tumors. Ann Oncol 16:162-168
55. Wittig B, Märten A, Dorbic T, et al (2001) Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: A first clinical phase I/II trial. Hum Gene Ther 12:267-278
56. Märten A, Renoth S, Heinicke T, et al (2003) Allogeneic dendritic cells fused with tumor cells: Preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14:483-494